I think the current trial (N=10) is too small to produce reliable efficacy results (negative or positive). Normally Phase 2a is a safety trial, with any efficacy data a bonus. The earlier trial was large enough to produce statistically significant data for DKD sufferers, but I believe had no FSGS sufferers at all, hence the need for the current FSGS Phase 2a trial.
But yes it would be disappointing if there was no indication at all of positive results for FSGS.
Ann: Quarterly Appendix 4C and Activities Report, page-207
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
0.045(10.2%) |
Mkt cap ! $262.7M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 49.0¢ | 44.0¢ | $2.019M | 4.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 15954 | 2 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |